China At Global Rare Disease Crossroads: CANbridge CEO
Reimbursement, Regulatory Changes Herald New Era?
Executive Summary
The Beijing/Boston-based bioventure shocked the industry with its recent announcement of the return of exclusive rights to an oncology assets in the greater China area to its US licensee, in an effort to focus squarely on rare diseases. CEO James Xue shares his views on this market in China in an exclusive interview with Scrip.
You may also be interested in...
Oncology, Rare Disease Drugs Dominate New China Approvals
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.
Shanghai Pharma Manufacturing Halves In April
China's main pharma hub of Shanghai reported sector output has plunged by more than half due in large part to the prolonged lockdown, while 58% of surveyed foreign companies in China across all industries project declining revenue.
Homegrown China Oral Antiviral Shows Early Promise
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.